Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

Abstract: Compositions and methods of promoting myelination in neurons are disclosed. The compositions include factors present in an umbilical cord blood derived macrophage cell population culture medium which can promote maturation of oligodendrocytes to promote myelination of neurons. Clinal and non-clinical uses of the compositions are also disclosed.

Abstract: The present disclosure relates to compositions and methods for enhanced engraftment of hematopoietic cells into the brain, and to therapeutic methods of treating central nervous system (CNS) diseases and disorders in subjects where replacing CNS pot macrophages (including microglia) and other tissue-resident macrophages with donor cells would be beneficial. In particular, the present disclosure relates to the use of a microglia depleting agent to enhance engraftment of hematopoietic-derived macrophages in the brain of a subject undergoing hematopoietic cell transplantation, to treat a subject suffering from a leukodystrophy and undergoing hematopoietic cell transplantation, to treat a subject suffering from a disease mediated by microglial dysfunction and undergoing hematopoietic cell transplantation, and to related methods. The present disclosure also relates to detection within cell populations of beMc? and microglia signatures.

Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product and an anti-inflammatory agent; methods for preparing such compositions; and methods of using such compositions in combination or in conjunction with each other for treatment of treating demyelinating conditions.

Abstract: The present invention relates to methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using cord blood tissue-derived mesenchymal stromal cells.

Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions comprising a DUOC-01 cell product; methods for preparing such compositions; and methods of using such compositions for treating demyelinating conditions.

Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

Abstract: The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells to treat Autism Spectrum Disorder.

Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

Abstract: The present disclosure relates to compositions and methods for enhanced engraftment of hematopoietic cells into the brain, and to therapeutic methods of treating central nervous system (CNS) diseases and disorders in subjects where replacing CNS pot macrophages (including microglia) and other tissue-resident macrophages with donor cells would be beneficial. In particular, the present disclosure relates to the use of a microglia depleting agent to enhance engraftment of hematopoietic-derived macrophages in the brain of a subject undergoing hematopoietic cell transplantation, to treat a subject suffering from a leukodystrophy and undergoing hematopoietic cell transplantation, to treat a subject suffering from a disease mediated by microglial dysfunction and undergoing hematopoietic cell transplantation, and to related methods. The present disclosure also relates to detection within cell populations of beMc? and microglia signatures.

Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product and an anti-inflammatory agent; methods for preparing such compositions; and methods of using such compositions in combination or in conjunction with each other for treatment of treating demyelinating conditions.

Abstract: The present disclosure relates to methods of treating cerebral palsy. More particularly, the present disclosure relates to methods of using a high dose of allogeneic umbilical cord blood to treat cerebral palsy.

Abstract: The present disclosure relates to methods of treating cerebral palsy and hypoxic-ischemic brain injury. More particularly, the present disclosure relates to methods of using cord blood or components thereof to treat cerebral palsy and hypoxic-ischemic brain injury. The present disclosure also relates to methods of assessing neuroprotective activity of a neuroprotective agent.

Abstract: The present disclosure provides compositions and methods for the treatment of demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product, derived from banked human umbilical cord blood (CB) mononuclear cells; methods for preparing such compositions; and methods of using such compositions for treatment of demyelinating conditions.

Abstract: The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The first population comprises stem cells derived from umbilical cord. The second population comprises ALDHbr cells. These ALDHbr cells can be administered to a patient immediately after isolation or can be primed in culture using a combination of cytokines for about 2 to about 7 days prior to transplantation. The methods of the invention are useful in accelerating time to neutrophil and/or platelet engraftment and immune reconstitution following myeloablative therapy.